MedAvante to Present at Cavendish Global Health Impact Forum
HAMILTON, N.J., Nov. 5, 2014 /PRNewswire/ -- MedAvante, Inc., a leading provider of technology-enabled signal detection solutions in global clinical trials of treatments for central nervous system (CNS) disorders, announced today it will be presenting at the Cavendish Global Health Impact Forum taking place November 10-13th at Oxford University in the United Kingdom. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.
"MedAvante is pursuing a unique and worthy mission of helping to ensure that better and safer treatments will reach the patients who need them faster," said Michael Moffat, Cavendish co-founder and President. "We are glad they will be at Oxford to share their important story of the systemic risks in clinical trials that can prevent new treatments from conclusively proving their efficacy. MedAvante's empirically based solution for this serious problem positions them to make a major contribution to improving the treatment of not only mental health disorders but also a wide range of conditions across many therapeutic areas."
"We are honored to be selected as a partner in this unique community and we very much look forward to telling our story at Oxford," said Paul M. Gilbert, MedAvante Chief Executive Officer. "Being included in the Cavendish community is powerful recognition of the innovative approach we've developed to improving the global drug development process by allowing promising new treatments a better opportunity to demonstrate their ability to benefit patients. We welcome the chance to interact with many of world's leading scientific minds, thought-leaders and generous individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world and who have the ability to assist MedAvante in making an important contribution to global health."
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.
About MedAvante
MedAvante is the leading global provider of technology-enabled signal detection solutions in clinical trials of treatments for central nervous system (CNS) disorders with more than a decade of experience improving scale-based diagnostic and outcome measurements. MedAvante standardizes rating scale administration and scoring through two primary services: the Virgil™ Investigative Study Platform for site-based assessments; and MedAvante® Central Ratings for live assessments by highly calibrated remote central clinicians. Supported by operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, visit www.medavante.com.
SOURCE MedAvante, Inc.
Share this article